Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S370000
Reexamination Certificate
active
07125875
ABSTRACT:
Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
REFERENCES:
patent: 3505055 (1970-04-01), von Schmeling et al.
patent: 3547917 (1970-12-01), Kulka et al.
patent: 3709992 (1973-01-01), von Schmeling et al.
patent: 3725427 (1973-04-01), Harrison et al.
patent: 3796800 (1974-03-01), Ariyan et al.
patent: 3879531 (1975-04-01), Ariyan et al.
patent: 3896223 (1975-07-01), Ariyan et al.
patent: 3932633 (1976-01-01), O'Brien et al.
patent: 4942143 (1990-07-01), Ohsaki et al.
patent: 4980346 (1990-12-01), Balogh et al.
patent: 5057142 (1991-10-01), Baasner et al.
patent: 5064825 (1991-11-01), Chakravarty et al.
patent: 5399674 (1995-03-01), Dannheim et al.
patent: 5438070 (1995-08-01), Eicken et al.
patent: 5498630 (1996-03-01), Phillion et al.
patent: 5514643 (1996-05-01), Rew et al.
patent: 5527763 (1996-06-01), Miyazaki et al.
patent: 5693667 (1997-12-01), Phillion et al.
patent: 5705513 (1998-01-01), Phillion et al.
patent: 5721264 (1998-02-01), Tanikawa et al.
patent: 5728693 (1998-03-01), Stevenson
patent: 5811411 (1998-09-01), Phillion et al.
patent: 5811428 (1998-09-01), Suto et al.
patent: 5817828 (1998-10-01), Tanikawa et al.
patent: 5834447 (1998-11-01), Phillion et al.
patent: 5840909 (1998-11-01), Tanikawa et al.
patent: 5846991 (1998-12-01), Tanikawa et al.
patent: 5849723 (1998-12-01), Phillion et al.
patent: 5922751 (1999-07-01), Cavalla et al.
patent: 6114365 (2000-09-01), Pevarello et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 38554/93 (1993-11-01), None
patent: 3205638 (1983-08-01), None
patent: 3220118 (1983-12-01), None
patent: 117082 (1984-08-01), None
patent: 177287 (1986-04-01), None
patent: 275312 (1988-07-01), None
patent: 286041 (1988-10-01), None
patent: 401030 (1990-12-01), None
patent: 0412404 (1991-02-01), None
patent: 0412404 (1991-02-01), None
patent: 422470 (1991-04-01), None
patent: 276177 (1992-01-01), None
patent: 538231 (1993-04-01), None
patent: 315502 (1993-06-01), None
patent: 569912 (1993-11-01), None
patent: 581960 (1994-02-01), None
patent: 603595 (1994-06-01), None
patent: 693480 (1996-01-01), None
patent: 928790 (1999-07-01), None
patent: 0928793 (1999-07-01), None
patent: 1437137 (1976-05-01), None
patent: 57-183768 (1982-11-01), None
patent: 62-123160 (1987-06-01), None
patent: 2-129171 (1990-05-01), None
patent: 2-275857 (1990-11-01), None
patent: 4-316559 (1992-11-01), None
patent: 11080137 (1999-03-01), None
patent: 11180965 (1999-07-01), None
patent: 2000186038 (2000-07-01), None
patent: WO91/00277 (1991-01-01), None
patent: WO93/07751 (1993-04-01), None
patent: WO93/25535 (1993-12-01), None
patent: WO94/22838 (1994-10-01), None
patent: WO95/18116 (1995-07-01), None
patent: WO 9519774 (1995-07-01), None
patent: WO96/00218 (1996-01-01), None
patent: WO 9610028 (1996-04-01), None
patent: WO199707131 (1997-02-01), None
patent: WO97/09315 (1997-03-01), None
patent: WO199708193 (1997-03-01), None
patent: WO 9716452 (1997-05-01), None
patent: WO199728161 (1997-08-01), None
patent: WO97/36875 (1997-10-01), None
patent: WO199749706 (1997-12-01), None
patent: WO98/28282 (1998-07-01), None
patent: WO98/52944 (1998-11-01), None
patent: WO98/56376 (1998-12-01), None
patent: WO98/57937 (1998-12-01), None
patent: WO99/00357 (1999-01-01), None
patent: WO99/21845 (1999-05-01), None
patent: WO99/24404 (1999-05-01), None
patent: WO99/31073 (1999-06-01), None
patent: WO99/57101 (1999-11-01), None
patent: WO99/58502 (1999-12-01), None
patent: WO99/62890 (1999-12-01), None
patent: WO00/02871 (2000-01-01), None
patent: WO00/17175 (2000-03-01), None
patent: WO00/24724 (2000-05-01), None
patent: WO00/26202 (2000-05-01), None
patent: WO00/26203 (2000-05-01), None
patent: WO00/31063 (2000-06-01), None
patent: WO00/39101 (2000-07-01), None
patent: WO00/39116 (2000-07-01), None
patent: WO00/47558 (2000-08-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 00/75120 (2000-12-01), None
patent: WO 01/10865 (2001-02-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/17995 (2001-03-01), None
patent: WO 01/56567 (2001-08-01), None
patent: WO200234727 (2002-05-01), None
patent: WO 03/013540 (2003-02-01), None
patent: 673552 (1967-05-01), None
patent: 723936 (1971-06-01), None
Chem. Abstr. 71 (1969) 61232q, Sherlock et al.
Aldrich Chemical Company, 1992 Catalog, p. 51, entries 25, 301-4 and 28, 457 -2, p. 98 entry A8, 980-4.
J. Heterocyclic Chem., 1970, vol. 7., No. 2, pp. 285-289.
Khim, Geterotsikl, Soedin., 1986, No. 2, pp. 277-278.
Annual Reports in Medicinal Chemistry, 1996, vol. 31, pp. 151-160.
Egypt J. Chem., 1979, vol. 22, No. 3, pp. 179-188.
M. Amoui et al., “Src family-selective tyrosine kinase inhibitor, PP1, inhibits both FcεRI- and Thy-1-mediated activation of rat basophilic leukemia cells”, European Journal of Immunology, vol. 27, pp. 1881-1886, 1997.
Marley et al., “The tyrosine kinase inhibitor ST1571, like interferon-β, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia”, Experimental Hematology, vol. 28, pp. 551-557, 2000.
Warmuth et al., “PP1, A Tyrosine Kinase Inhibitor Specific for SRC-Family Kinases, Selectively inhibits survival of BCR-ABL Expressing Myeloid Cells”, Blood, vol. 94, No. 10, Pt. Suppl. 387a, 1999.
Hanke et al., “Discovery of a Novel, Potent, and SRC Family-selective Tyrosine Kinase Inhibitor”, The Journal of Biological Chemistry, vol. 271, No. 2, pp. 695-701, 1996.
Tatton et al., “The Selective SRC Kinase Inhibitor PP1 also Inhibits C-KIT and BCR-ABL Tyrosine Kinase and Induces Apoptosis in Mast Cell Leukaemia, CML and AML Cells”, Blood, vol. 96, No. 11 Pt. 1 81a, 2000.
Druker et al., “Activity of an ABL Specific Tyrosine Kinase Inhibitor in Patients with BCR-ABL Positive Acute Leukemias, Including Chronic Myelogenous, Leukemia in Blast Crisis”, Blood, vol. 94, 697a, 1999.
Mahon et al., “Selection and Characterization of BCR-ABL Positive Cell Lines with Differential Sensitivity to the Signal Transduction Inhibitor STI751: Mechanisms of Resistance”, Blood, vol. 94, Suppl. 1, 656a, 1999.
Talpaz et al., “Downregulation of BCR-ABL Expression and Kinase Activity but Reciprically Increased phosphorylation of Specific Proteins in STI-571 Resistant K562 Cells: Evidence for the Involvement of other Tyrosine Phosphoproteins in Signaling and Survival”, Blood, vol. 96, No. 11, Part 1, 345a, 1980.
Tipping et al., Response of ST1571-Resistant Cells to Other Chemotherapeutic Drugs and Signal Transduction Inhibitors, Blood, vol. 96, No. 11 Part 1, 98a, 2000.
Topaly et al., “Synergistic Activity of the New ABL-Specific Tyrosine Kinase Inhibitor STI571 and Chemotherapeutic Drugs on BCR-ABL-positive Chronic Myelogenous Leukemia Cells”, Leukemia, vol. 15, pp. 342-347, 2001.
Theising et al., “Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents Bcr-Abl positive cells”, Blood, vol. 96, No. 9, pp. 3195-3199, 2000.
Kano et al., “In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents”, Blood, vol. 97, No. 7, pp. 1999-2007, 2001.
Dorsey et al., “The Pyrido[2,3-d]pyrimidine Derivative PD180970 Inhibits p210Bcr-AblTyrosine Kinase and Induces Apoptosis of K562 Leukemic Cells”, Cancer Research, vol. 60, pp. 3127-3131, 2000.
Weisberg et al., “Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells lines”, Blood, vol. 95, No. 11, pp. 3498-3505, 2000.
La Rosée et al., “Activity of the Bcr-Abl Kinase Inhibitor PD180970 against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI571)1”, Cancer Research, vol 62, pp. 7149-7153, 2002.
Mahon et al.,
Barrish Joel C.
Chen Ping
Das Jagabandhu
Doweyko Arthur M. P.
Lee Francis Y. F.
Bristol--Myers Squibb Company
Solola Taofiq
VanAtten Mary K.
LandOfFree
Cyclic protein tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic protein tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic protein tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3706737